Coronavirus Vaccine

Serum set for deal with Centre soon; to supply vaccine at Rs 250 a dose

By Administrator_ India

Capital Sands

The biggest vaccine maker of the world, Serum Institute of India (SII), which has applied to the regulator for an emergency use authorisation  for the Covishield vaccine, is close to signing a supply contract with the Union government. The price is likely to be fixed at Rs 250 per dose of the vaccine, people in the know said.

While there’s lack of clarity on the number of doses that would be procured from the Pune-based company, sources indicated around 60 million could be available soon. By January-February, it’s expected to have at least 100 million doses for the Indian government, if it chooses to procure. Adar Poonawalla, CEO of Serum Institute, said in a Twitter message on Monday, “As promised, before the end of 2020, @SerumInstIndia has applied for emergency use authorisation for the first made-in-India vaccine, Covishield. This will save countless lives, and I thank the Government of India and Sri @narendramodi ji for their invaluable support.”

There is still time before SII can start supplying to the low and medium income countries through Gavi (the vaccine alliance via public-private global health partnership), said an official.

So far, SII has over 40 million doses ready, but the demand is huge. The company has to supply 200 million doses of Covishield and Novavax vaccine candidate to Gavi and Bill and Melinda Gates Foundation at Rs 250 or $3 per dose for 2021 to distribute in low and medium income countries. Also, it will supply 1 billion doses to AstraZeneca, of which around 50 per cent will be for India.

The government has indicated that it would need 60 million doses to vaccinate 30 million people in the priority list. These would include healthcare and frontline essential services workers including municipality staff and public transport operators etc. Subsequently, this would be expanded to include the vulnerable population who have serious co-morbidities, and then to people above 50.

The vaccine would be available in the private market too by March-April, but at a higher price. Poonawalla has indicated a price of around Rs 500-600 per dose in the private market.

Administrator_India

About Author

Leave a comment

Your email address will not be published. Required fields are marked *

You may also like

Two-Day Coronavirus Vaccine Dry Run Starts In Four States Today
Coronavirus Vaccine

COVID-19 vaccines, if developed in India, need antibody response in at least 50% cases for approval

By Administrator_India Capital Sands According to the draft guidelines for the development of COVID-19 vaccines, a vaccine developed in India
Coronavirus Vaccine

Global indices cheer as Moderna’s Covid vaccine data boost sentiment

By Administrator_ India Capital Sands Global stocks eyed a fresh record high on Monday as signs of economic recovery in